Phathom Pharmaceuticals/$PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Primary listing
Employees
427
Headquarters
Website
PHAT Metrics
BasicAdvanced
$766M
-
-$4.71
0.45
-
Price and volume
Market cap
$766M
Beta
0.45
52-week high
$18.40
52-week low
$2.21
Average daily volume
1.2M
Financial strength
Current ratio
2.384
Quick ratio
2.187
Long term debt to equity
-136.196
Total debt to equity
-141.559
Interest coverage (TTM)
-3.70%
Profitability
EBITDA (TTM)
-268.266
Gross margin (TTM)
86.91%
Net profit margin (TTM)
-289.51%
Operating margin (TTM)
-235.88%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-59.03%
Return on equity (TTM)
103.23%
Valuation
Price to revenue (TTM)
6.757
Price to book
-1.9
Price to tangible book (TTM)
-1.9
Price to free cash flow (TTM)
-2.804
Free cash flow yield (TTM)
-35.67%
Free cash flow per share (TTM)
-3.923
Growth
Revenue change (TTM)
1,049.82%
Earnings per share change (TTM)
-8.32%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Bulls say / Bears say
VOQUEZNA recorded more than 390,000 prescriptions filled and $28.5 million in net revenue in Q1 2025, pointing to strong early demand.
The FDA's Orange Book update grants VOQUEZNA full 10-year New Chemical Entity exclusivity until May 3, 2032, ensuring a lengthy period without generic competition.
VOQUEZNA demonstrates high profitability potential, highlighted by an 86.23% trailing twelve-month gross margin, indicating strong pricing power and efficient costs.
Phathom reported a net loss of $94.3 million in Q1 2025, showing the company remains unprofitable despite strong initial sales.
General and administrative expenses jumped to $94.5 million in Q1 2025, up 52% year-over-year, raising concerns about cost control and cash burn.
The company halted its planned Phase 2 trial for eosinophilic esophagitis, delaying pipeline expansion and future growth potential due to exclusivity and funding challenges.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $766M as of September 18, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of September 18, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.